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Spinal and bulbar muscular atrophy (SBMA), a pro-
gressive degenerative disorder, is caused by a
CAG/glutamine expansion in the androgen receptor
(polyQ AR). Recent studies demonstrate that skeletal
muscle is an important site of toxicity that contrib-
utes to the SBMA phenotype. Here, we sought to
identify critical pathways altered in muscle that un-
derlie disease manifestations in AR113Q mice. This
led to the unanticipated identification of gene
expression changes affecting regulators of carbohy-
drate metabolism, similar to those triggered by
denervation. AR113Q muscle exhibits diminished
glycolysis, altered mitochondria, and an impaired
response to exercise. Strikingly, the expression of
genes regulating muscle energy metabolism is
rescued following peripheral polyQ AR gene
silencing by antisense oligonucleotides (ASO), a
therapeutic strategy that alleviates disease. Our
data establish the occurrence of a metabolic imbal-
ance in SBMA muscle triggered by peripheral
expression of the polyQ AR and indicate that alter-
ations in energy utilization contribute to non-
neuronal disease manifestations.INTRODUCTION
The progressive degeneration of the neuromuscular system that
occurs in spinal and bulbar muscular atrophy (SBMA) results in
skeletal muscle weakness and atrophy and the loss of lower
motor neurons in the spinal cord and brainstem (Chua and Lie-
berman, 2013; Lieberman and Fischbeck, 2000). Clinical onset
typically occurs in young to midlife adults and is slowly progres-
sive. The disease is X linked and caused by expansion of a CAG/Cell Re
This is an open access article under the CC BY-Nglutamine tract in the coding region of the first exon of the gene
encoding the androgen receptor (AR). Ligand binding to the
polyglutamine AR (polyQ AR) promotes nuclear translocation
and protein unfolding. Both of these steps are required for path-
ogenesis and underlie the occurrence of disease only in men
(Katsuno et al., 2002; Takeyama et al., 2002). While the polyglut-
amine tract expansion leads to a partial loss of the AR’s transac-
tivation function (Chamberlain et al., 1994; Kazemi-Esfarjani
et al., 1995; Lieberman et al., 2002; Mhatre et al., 1993), and
this may contribute to features of androgen insensitivity, neuro-
muscular degeneration is mediated by a toxic gain of function
conferred by the misfolded protein. As with all of the polyglut-
amine disorders, the mechanisms that lead to progressive func-
tional impairment are poorly understood, and disease-modifying
therapies are currently unavailable.
Studies of SBMA patients and genetic mousemodels have es-
tablished that skeletal muscle is an important site of toxicity and
an attractive therapeutic target. These studies have demon-
strated both denervation and myofiber degeneration in muscle
biopsies from SBMA subjects (Soraru` et al., 2008). This mixed
pathology reflects the occurrence of myopathic symptoms in
SBMA patients, including early-onset muscle cramps and
elevated levels of serum creatine kinase that exceed those de-
tected in pure denervating diseases (Atsuta et al., 2006; Rhodes
et al., 2009). Similarly, analysis of a mouse model of SBMA
generated through gene targeting (AR113Q mice) demonstrated
the presence of both myopathic and denervating changes in
skeletal muscle (Yu et al., 2006a). Highlighting the contribution
of skeletal muscle to neuromuscular degeneration are transgenic
mice that overexpress the wild-type AR only in muscle and
exhibit an SBMA-like phenotype (Johansen et al., 2009; Monks
et al., 2007). Similar results have been reported recently in
mice overexpressing the polyQ AR only in muscle (Ramzan
et al., 2015). Moreover, genetic overexpression of IGF-1 in skel-
etal muscle alleviates disease in a transgenic mouse model of
SBMA (Palazzolo et al., 2009), emphasizing the potential utility
of targeting peripheral tissues in this disease. This notion is
supported by treatment of AR113Q or polyQ AR bacterialports 17, 125–136, September 27, 2016 ª 2016 The Author(s). 125
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
artificial chromosome (BAC) transgenic mice with subcutane-
ously (s.c.) administered antisense oligonucleotides (ASOs) tar-
geted against AR (Lieberman et al., 2014). This treatment
diminishes polyQ AR expression in the periphery, but not CNS,
and rescues disease. These findings are corroborated by genetic
studies demonstrating that deletion of a floxed polyQ AR allele
only in skeletal muscle prevents disease in BAC transgenic
mice (Cortes et al., 2014). Taken together, this body of work
has established the importance of polyQ AR expression in skel-
etal muscle to the SBMA phenotype.
Here, we sought to define critical pathways altered in AR113Q
muscle that contribute to the disease phenotype. To accomplish
this, we mined gene expression data from skeletal muscle of
wild-type and AR113Q males. This approach led to the unantic-
ipated identification of a cohort of genes that regulate carbohy-
drate metabolism in muscle that are expressed at diminished
levels in AR113Q mice. We provide evidence of decreased
glycolysis and altered mitochondria in AR113Q muscle and
demonstrate that these changes are functionally significant by
impacting the response to exercise. Moreover, we establish
that subcutaneous administration of ASOs to AR113Q males
rescues the expression of diverse genes controlling energy
metabolism in muscle. Our data provide evidence of metabolic
alterations in SBMA muscle and demonstrate that these
changes are triggered by peripheral expression of the polyQ AR.
RESULTS
Decreased Expression of Carbohydrate-Metabolism-
Related Genes in AR113Q Muscle
We sought to understand the mechanisms by which expression
of the polyQ AR in skeletal muscle contributes to the phenotype
of AR113Q knockin mice. To uncover pathways that are altered
in disease, we harvested quadriceps muscle fromwild-type (WT)
and AR113Q males at 14 weeks of age. RNA sequencing (RNA-
seq) was used to characterize gene expression, and pairwise
analysis uncovered 909 genes differentially expressed by at least
1.5-fold in quadriceps muscle of AR113Q compared to WT mice
(Tables S1 and S2). Pathway analysis by Gene Ontology (GO)
terms revealed altered expression in AR113Q muscle of regula-
tors of carbohydrate metabolism (Figure 1A). Detailed examina-
tion uncovered significantly decreased expression of nine genes
encoding enzymes in the glycolytic pathway (Figure 1B). In
contrast, none of the genes encoding enzymes in the tricarbox-
ylic acid (TCA) cycle were expressed at significantly different
levels in AR113Q muscle. Broad effects on the expression of
genes regulating energy metabolismwere confirmed in indepen-
dent cohorts of WT and AR113Q mice by analyzing both a
hindlimb muscle (quadriceps) and a pelvic floor muscle that
expresses high levels of the polyQ AR (levator ani/bulbocaverno-
sus [LA/BC]). We confirmed by real-time qPCR significantly
decreased expression of genes encoding upstream signaling
regulators of carbohydrate metabolism (Prkar2a and Prkag3),
and mediators of glucose uptake (Slc2a4), glycolysis (Hk2),
and glycogenolysis (Phkg1 and Pygm) (Figure 1C). Similarly,
western blot demonstrated decreased expression of glycolytic
enzymes HK2 and GAPDH, but not the mitochondrial respiratory
chain component SDHA, in AR113Q muscle (Figure 1D). These126 Cell Reports 17, 125–136, September 27, 2016data demonstrate an unexpected decrease in the expression
of carbohydrate-metabolism-related genes in AR113Q skeletal
muscle.
To glean insight into the functional effect of these gene expres-
sion changes, WT and AR113Q mice were run on an inclined
treadmill for 15 min at increasing speed, and quadriceps muscle
was harvested for metabolomics analysis. This intense exercise
protocol was designed to favor anaerobic metabolism (Koch and
Britton, 2001). Tissues were collected under continuous anes-
thesia and flash frozen in liquid nitrogen using a procedure that
maintains unaltered levels of metabolites in muscle (Overmyer
et al., 2015). Samples were analyzed by liquid chromatog-
raphy-mass spectrometry (LC-MS) and gas chromatography-
mass spectrometry (GC-MS). In accordance with gene expres-
sion analysis, AR113Q muscle harvested during exercise
contained significantly lower levels of the glycolytic intermedi-
ates fructose 1,6-bisphosphate (FBP), the product of the rate-
limiting and irreversible step in glycolysis, and pyruvate (PYR)
(Figures 2A and 2D). A similar trend was detected in levels of
2- and 3-phosphyoglycerate (2PG/3PG), but these did not reach
statistical significance because of variability between samples.
In contrast, the TCA cycle intermediates citrate/isocitrate (CIT/
ICIT), a-ketoglutarate (AKG), fumarate (FUM), and malate
(MAL) were unchanged between cohorts (Figures 2B and 2D).
These data are indicative of a more severe functional impairment
of glycolysis than the TCA cycle and are consistent with the
broad decrease in expression of carbohydrate-metabolism-
related genes in AR113Q muscle (Figure 1). Metabolomics addi-
tionally identified significantly diminished levels of NAD and
NADP in AR113Q muscle, findings that are suggestive of lower
metabolism through the glycolytic pathway (Figure 2C). In
contrast, no difference in levels of ATPwas observed (Figure 2C),
consistent with the notion that the TCA cycle was relatively intact
in mutant muscle.
Mitochondrial Defects in AR113Q Skeletal Muscle
We next sought to establish the extent to which mitochondrial
abnormalities accompanied alterations in the expression of car-
bohydrate-metabolism-related genes in AR113 muscle. Prior
studies identified mitochondrial defects in cellular models of
SBMA and showed diminished expression of several mitochon-
drial genes in AR113Q muscle (Ranganathan et al., 2009). We
performed transmission electron microscopy (TEM) on WT and
AR113Q soleus muscles (Figure 3A). The soleus is rich in slow-
twitch oxidative fibers that contain a large number of mitochon-
dria. While sarcomere architecture was intact in mutants, we
observed a significant decrease in themean area occupied by in-
termyfibrillar mitochondria (Figures 3A and 3B). Similarly, mtDNA
copy number was significantly decreased in the LA/BC (Fig-
ure 3C). Moreover, 20% of mitochondria in AR113Q muscle
were either focally swollen or tightly associated with vesicles,
many of which resembled autophagosomes (Figures 3A, 3D,
and S1). This finding is consistent with the robust activation of
macroautophagy previously demonstrated in AR113Q skeletal
muscle (Chua et al., 2014; Yu et al., 2011) and suggests the
occurrence of increased mitophagy. To test functional status,
mitochondria were isolated from WT or AR113Q muscle for
Seahorse analysis. Mitochondria from quadriceps muscles of
Figure 1. Decreased Expression of Carbohydrate Metabolism Genes in AR113Q Skeletal Muscle
(A and B) Quadriceps muscles from wild-type (WT) or AR11Q males (n = 3/group) were harvested at 14 weeks of age and gene expression was analyzed by
RNA-seq. (A) GO terms of differentially expressed genes (R1.5-fold) related to carbohydrate metabolism. p values by false discovery rate are indicated.
(B) Relative expression of genes encoding glycolytic or TCA cycle enzymes in AR113Q versusWTmuscle. Shown in blue are genes whose expression is changed
byR1.5-fold and in black genes whose expression is changed by <1.5-fold.
(C) Expression of carbohydrate metabolism-related genes in quadriceps and LA/BC muscles of WT and AR113Q mice (mean ± SEM; n = 5/group). **p < 0.01;
***p < 0.001 by Student’s t test.
(D) Western blots of HK2, GAPDH, and SDHA in lysates from LA/BC muscles of WT and AR113Q mice.AR113Q mice were significantly more uncoupled than those
from WT mice (Figure 3E). These findings suggest that a fraction
of mitochondria in AR113Q muscle are dysfunctional.
Altered Response of AR113Q Mice to Exercise
Our observations of altered carbohydrate-metabolism-related
gene expression and mitochondrial abnormalities led us to
compare metabolic rate and substrate utilization in WT and
AR113Qmice. Oxygen consumption (VO2, mg/kg/hr) and energyexpenditure (kcal/kg/hr) were quantified by CLAMS (the
Comprehensive Laboratory Animal Monitoring System) analysis
for three consecutive days. No significant differences in energy
metabolism during home cage activity were detected between
the two groups (Figure 4A). Similarly, serum glucose and insulin
levels as measured during a glucose tolerance test were un-
changed in AR113Q males (Figure S2). However, when mice
were challenged to perform acute exercise, significant differ-
ences between these cohorts emerged (Figure 4B). Mice wereCell Reports 17, 125–136, September 27, 2016 127
Figure 2. Energy Metabolites in Skeletal
Muscle during Exercise
WT and AR113Q male mice at 14 weeks were run
at increasing speeds on an inclined treadmill for
15 min, and quadriceps muscles were then har-
vested for analysis.
(A) Glycolytic metabolites fructose 1,6-bis-P
(FBP), 2- and 3-phosphyglycerate (2PG/3PG), and
pyruvate (PYR).
(B) TCA cycle metabolites citrate/isocitrate (CIT/
ICIT), a-ketoglutarate (AKG), fumarate (FUM), and
malate (MAL).
(C) NAD, NADP, and ATP levels (mean ± SEM;
n = 4/group). *p < 0.05; **p < 0.01 by Student’s
t test.
(D) Schematic highlighting measured glycolytic
and TCA cycle metabolites. Metabolites signifi-
cantly different between WT and AR113Q are in
red, unchanged in blue, and not measured in
black.tasked to run on an inclined treadmill at increasing speeds for
30 min or until exhaustion. While both groups of mice ran the
same time and distance, AR113Q mice expended more energy
and consumed more oxygen to complete this task. These differ-
ences were consistent with partial mitochondrial uncoupling in
AR113Qmuscle (Figure 3E), andmay reflect enhanced utilization
of fats or amino acids as alternative energy sources to
carbohydrates.
The metabolic alterations in AR113Q muscle after intense,
acute exercise prompted us to determine whether mutant males
would respond aberrantly to modest, chronic exercise. To test
this possibility, WT and AR113Q males were randomly assigned
to exercise or rest cohorts, with exercise cohorts completing a
mild running regimen from 8 to 14 weeks of age. Mice were run128 Cell Reports 17, 125–136, September 27, 20165 days per week on a horizontal treadmill
for 30 min at 10 m/minute, while control
mice were placed on the immobile appa-
ratus for the same duration to control for
confounding effects from environmental
enrichment. This low-intensity endurance
exercise protocol was designed to favor
oxidative metabolism. All WT mice
completed the 6 weeks of training, while
only seven out of ten AR113Q mice in
the exercise cohort (70%) and six out of
eight AR113Q mice in the rest cohort
(75%) survived until the end of the study
(Figure 5A). This is consistent with previ-
ous analysis of lifespan in AR113Q mice
(Yu et al., 2006a) and indicates that exer-
cise did not impact survival.While chronic
exercise significantly improved forelimb
grip strength of WTmales, it had no effect
on AR113Q mice (Figure 5B). Moreover,
analysis of soleus and gastrocnemius
muscles showed that both type I and
type II fibers were significantly reducedin size in exercised AR113Q mice, whereas WT muscle showed
the opposite effect (Figures 5C and 5D). Notably, exercise did
not alter polyQ AR protein levels or aggregation inmutantmuscle
(Figure S3). These data demonstrate an aberrant response to
chronic, low-intensity exercise in AR113Q males.
Peripheral polyQ AR Gene Suppression Rescues
Expression of Muscle Metabolism Genes
We hypothesized that peripheral expression of the polyQ AR
contributed to altered expression of carbohydrate metabolism-
related genes in AR113Q muscle. This notion was based on
recent studies demonstrating that subcutaneous administration
of Ar-targeted ASO decreases expression of the mutant protein
in skeletal muscle, but not in spinal cord, and ameliorates
Figure 3. Mitochondrial Defects in the Skeletal Muscle of AR113Q Mice
(A) Representative TEMs of soleus muscle from WT and AR113Q males at 14 weeks. Inset shows vesicle-associated mitochondria. Scale bar, 500 nm.
(B) Mean area ± SEM of intermyofibrillar mitochondria (n = 3 mice/group;R90 mitochondria/mouse). ***p < 0.001 by Student’s t test.
(C) mtDNA copy number in the LA/BC muscle of WT and AR113Q mice measured as a ratio between mtDNA (D loop) and genomic DNA (b2 m) (mean ± SEM;
n = 8/group). **p < 0.01 by Student’s t test.
(D) Percentage of mitochondrial with focal swellings or associated with vesicles (mean ± SEM; n = 3/group; R90 mitochondria per mouse). ***p < 0.001 by
Student’s t test.
(E) Relative uncoupling of mitochondria isolated from quadriceps muscles of WT and AR113Q mice (mean ± SEM; n = 3/group). **p < 0.01 by Student’s t test.disease (Lieberman et al., 2014). To test this hypothesis,
AR113Q males received a therapeutic dose of Ar-targeted
ASO (50 mg/kg per week, s.c.) from 6 to 14 weeks of age. Quad-
ricepsmuscles were harvested and gene expression determined
by RNA-seq. This analysis demonstrated that nearly three-quar-
ters of the gene expression differences detected in the compar-
ison of AR113Q versus WT muscle were rescued by peripheral
treatment with ASO (Figure 6A; Tables S1 and S3). As this inter-
vention alleviates the disease phenotype, we focused on the 666
genes whose expression was responsive to ASO administration.
Analysis of GO terms demonstrated that many of the carbohy-
drate metabolism-related genes whose expression was alteredin AR113Q muscle were rescued by ASO treatment (Figure 6B).
Notably, of the 21 ASO-responsive genes identified in the GO
term ‘‘hexose metabolic process,’’ 19 were expressed at lower
levels in AR113Qmuscle. Moreover, one of the genes expressed
at higher levels in mutant muscle was Cpt1a, encoding a protein
that is essential for uptake of long-chain fatty acids into mito-
chondria. In addition, of the nine genes encoding glycolytic en-
zymes that were expressed at lower levels in AR113Q muscle
(Figure 1B), all except Gapdh and Pgk1 were rescued by
treatment with ASO (Tables S1, S2). We confirmed that treat-
ment with Ar-targeted ASO, but not a non-targeted control,
diminished expression of AR mRNA and rescued the expressionCell Reports 17, 125–136, September 27, 2016 129
Figure 4. Enhanced Energy Expenditure
and Oxygen Consumption in AR113Q Mice
during Exercise
(A) Home-cage energy expenditure (kcal/kg/hr)
and O2 consumption (mg/kg/hr) in WT and
AR113Q mice at 14 weeks, as measured during
three consecutive days (mean ± SEM; n = 9/
group).
(B) Energy expenditure (kcal/kg/hr) and O2 con-
sumption (mg/kg/hr) in WT and AR113Q mice
during acute running at increasing speeds on
an inclined treadmill (mean ± SEM; n = 9/group).
*p < 0.05 for all time points from 5 to 25 min.of carbohydrate metabolism-related genes in skeletal muscle
(Figure 6C). In addition, we identified ASO-responsive expres-
sion of a limited set of mitochondria-related genes including
Ppargc1b (peroxisome proliferator-activated receptor gamma,
coactivator 1 beta [PGC-1b]), a transcriptional co-activator of
genes regulating mitochondrial function (Villena, 2015), and
Bbc3 (BCL2 binding component 3), a BCL-2 family member
that induces mitochondrial outer membrane permeabilization
(Huang and Strasser, 2000) (Figure 6D).
Altered Expression of Upstream Regulators of Energy
Homeostasis
Given the large number of genes related to carbohydrate meta-
bolism whose expression was diminished in AR113Q muscle,
we reasoned that activity of upstream regulators of this pathway
mightbealtered. Toexplore thispossibility,weanalyzed thesetof
ASO-responsive genes identified through RNA-seq by Ingenuity
Pathway Analysis (IPA). This analysis identified several interre-
lated nodes of canonical pathways and upstream regulators
that converge to influence energy homeostasis (Figure 7A).
Among these pathways were genes associated with protein ki-
nase A (PKA) (Prkar2a; p = 4.51 3 106) (Table S3) and AMPK
(50 AMP-activated protein kinase) signaling, including the g3 reg-
ulatory subunit of AMPK (Prkag3; p = 7.72 3 1014). In skeletal
muscle, AMPK regulates glucose transport as well as mitochon-
drial function and biogenesis (reviewed in Lantier et al., 2014). IPA
also identified transcription factors SRF (serum response factor)
(p = 7.55 3 1012) and NR4A1 (nuclear receptor subfamily 4,
group A, member 1) (p = 9.18 3 1013). NR4A1 is an orphan re-
ceptor in the steroid-thyroid hormone-retinoid receptor super-
family that is induced by diverse stimuli in skeletal muscle,
including PKA signaling (Kanzleiter et al., 2009; Maxwell et al.,130 Cell Reports 17, 125–136, September 27, 20162005), as well as the transcription factor
SRF (Iacono et al., 2013; Jin et al., 2011).
As NR4A1 regulates skeletal muscle
expression of genes influencing glucose
transport, insulin signaling, glycolysis,
and glycogenolysis (Chao et al., 2007,
2009; Kanzleiter et al., 2010; Maxwell
et al., 2005), we sought to confirm its
altered expression in AR113Q muscle.
Significantly decreased expression of
NR4A1 mRNA was found in AR113Q
versus WT quadriceps, and this defectwas rescued by treatment with Ar-targeted, but not control,
ASO (Figure 7B). In contrast, no changes in the expression of
genes encoding NR4A1 or HK2 were detected in spinal cord of
AR113Q mice (Figure S4), indicating that altered expression
of carbohydrate-metabolism-related genes was a phenotype
more robustly manifest by skeletal muscle. Analysis of RNA-seq
data indicated that 17 genes reported to respond to alterations
in NR4A1 expression (Pearen and Muscat, 2010) were differen-
tially expressed in AR113Q versus WT quadriceps (Tables S1
and S4), suggesting that the activity of this transcription factor
was decreased in mutant muscle. Notably, the majority of these
genes encoded proteins involved in carbohydrate metabolism,
and the expression of 13 of themwas restored by ASO treatment.
Prior studies have demonstrated that expression of NR4A1 is
significantly reduced in skeletal muscle after denervation (Chao
et al., 2007). We confirmed this observation in gastrocnemius
muscle of WT mice following sciatic nerve transection and addi-
tionally demonstrated decreased expression of the NR4A1-
responsive genes Scl2a4 and Phkg1 (Figure 7C). As these genes
were also downregulated in AR113Q muscle and restored by
ASO, we conclude that peripheral polyQ AR induces changes
in muscle that mimic those triggered by denervation to influence
the expression of metabolic genes. This likely reflects an under-
lying impairment of communication between skeletal muscle and
innervating motor neurons that influences the expression of reg-
ulators of skeletal muscle energy metabolism and the response
to exercise in AR113Q mice.
DISCUSSION
We demonstrate previously unrecognized alterations in skeletal
muscle energy metabolism that are a consequence of peripheral
Figure 5. Effects of Chronic Exercise in
AR113Q Mice
WT and AR113Q mice were run on a treadmill five
times per week for 30 min at 10 m/minute for
6 weeks, from 8 to 14 weeks of age. Control mice
(‘‘rest’’) were placed on an immobile treadmill
apparatus for an equivalent time.
(A) Survival of AR113Q males was not altered by
exercise. p > 0.05 by log-rank analysis.
(B) Forelimb grip strength (g) of WT and AR113Q
mice assessed at the end of the 6-week training
period (mean ± SEM; nR 4WTmice/group; nR 6
AR113Qmice/group). *p < 0.05; **p < 0.01 by one-
way ANOVA.
(C) Left: immunofluorescence staining for type I
slow-twitch heavy-chain myosin (green) and type
II fast-twitch heavy-chain myosin (red) in soleus/
gastrocnemius muscles. Basement membrane
was stained with wheat germ agglutinin (green);
nuclei were stained by DAPI (blue). Scale bar,
20 mm. Right: relative mean fiber size ± SEM;
nR 4 mice/group,R 25 fibers/mouse. **p < 0.01,
***p < 0.001 by one-way ANOVA.
(D) Fiber size distribution of type I and type II fibers
in WT and AR113Q mice (nR 4 mice/group,R25
fibers/mouse).polyQ AR expression (Figure S5). RNA-seq data led to the dis-
covery of decreased expression of numerous genes regulating
carbohydrate metabolism in skeletal muscle of mutant males.
These changes are accompanied by evidence of diminished ac-
tivity of regulators of glucose utilization, including upstreamCell Repsignaling pathways controlled by PKA
and AMPK and downstream transcription
factors such as SRF and NR4A1.We sug-
gest that diminished energy utilization
through glycolysis leads to a shift toward
alternative energy sources such as lipids
and that this contributes to mitochondrial
damage and dysfunction. The conse-
quences of these metabolic alterations
are evident during intense, acute exercise
that favors anaerobic metabolism and
following chronic, low-intensity endur-
ance exercise that favors oxidative
metabolism.
Interestingly, we note that similar
alterations in gene expression occur
following sciatic nerve transection in
WT mice. Our observations are consis-
tent with prior reports indicating that
loss of b-adrenergic signaling following
denervation contributes to diminished
PKA activity and reduced expression of
NR4A1 and its target genes (Chao
et al., 2007). Metabolic alterations char-
acterized by a glycolytic to oxidative
shift also occur in skeletal muscle
of transgenic mice expressing mutantG86R SOD1 (Palamiuc et al., 2015), and clinical studies have
demonstrated that approximately two-thirds of patients with
amyotrophic lateral sclerosis are hypermetabolic (Desport
et al., 2005). These findings support the concept that muscle
energy metabolism is altered in degenerative motor neuronorts 17, 125–136, September 27, 2016 131
Figure 6. Peripheral ASO Treatment Res-
cues Expression of Metabolic Genes in
AR113Q Muscle
Male mice (n = 3/group) were treated with ASO
(50 mg/kg per week, s.c.) or vehicle from 6 to
14 weeks of age, and gene expression in skeletal
muscle was analyzed by RNA-seq.
(A) Heatmap shows genes differentially expressed
(R1.5-fold) in quadriceps muscle of AR113Q
versus wild-type (WT) mice (top row). Differential
expression in ASO-treated AR113Q versus WT
muscle (bottom row) highlights genes rescued by
ASO (expression difference <1.5-fold). Activated
genes are shown in red and repressed genes in
blue.
(B) GO terms of differentially expressed genes
(R1.5-fold) related to carbohydrate metabolism
that are rescued by treatment with ASO. p values
by false discovery rate are indicated.
(C and D) Relative mRNA levels in quadriceps
muscle of WT, AR113Q, and AR113Q mice
treated with AR-targeted ASO or control ASO
(SCRAMBLE) from 6 to 14 weeks of age (mean ±
SEM; n = 3/group). *p < 0.05; **p < 0.01; ***p <
0.001 by one-way ANOVA. Expression of AR and
carbohydrate metabolism-related genes (C) and
mitochondrial-related genes (D) is shown.diseases as a consequence of denervation. Our data indicate
that similar changes occur in AR113Q mice due to peripheral
expression of the polyQ AR. The identification of ASO-sensitive
changes in the expression of carbohydrate metabolism genes
complements previously characterized changes in markers of
denervation, including acetylcholine receptor-a subunit and
myogenin mRNAs, that are also abnormal in AR113Q muscle
and rescued by peripheral gene knockdown (Lieberman et al.,
2014). Taken together, these findings indicate that peripherally
expressed polyQ AR disrupts communication between motor
neurons and skeletal muscle and recapitulates gene expression
and metabolic alterations in skeletal muscle that have been
previously characterized to occur following injury to motor neu-
rons or their axons. Prior studies have demonstrated impaired
retrograde labeling of spinal motor neurons in AR113Q mice
despite the absence of morphological abnormalities at the
neuromuscular junction that are evident by light microscopy
(Kemp et al., 2011), suggesting that disruption of nerve-muscle
communication may initially reflect functional, rather than struc-
tural changes.132 Cell Reports 17, 125–136, September 27, 2016The model of pathogenesis that we
present (Figure S5) places alterations in
carbohydrate metabolism upstream of
the mitochondrial abnormalities that
were identified in AR113Q muscle,
including diminished mitochondrial num-
ber, increased mitophagy, and partial
mitochondrial uncoupling. This latter ef-
fect may be a consequence of damage
by reactive oxygen species (Mailloux
and Harper, 2012), perhaps arising dueto the use of fats as an important, alternative energy source.
This model is based on gene expression analysis that showed
a large number of changes involving regulators of glucose
metabolism compared to components of the TCA cycle and me-
tabolomics analysis that showed significantly lower levels of
glycolytic intermediates without alterations in TCA cycle metab-
olites. We note that it is also possible that the polyQ AR may
directly damage mitochondria, as previously suggested (Ranga-
nathan et al., 2009), and that in this setting, alterations in glycol-
ysis may occur secondary to mitochondrial damage. Indeed, it is
possible that both pathways are directly targeted by the polyQ
AR. Further analysis to clarify the relationship between changes
in glycolysis and mitochondria in SBMAmuscle will be an impor-
tant focus of future studies.
The occurrence of metabolic abnormalities in AR113Qmuscle
underlying an impaired response to exercise suggests that these
changes are important aspects of the neuromuscular phenotype
of SBMA patients. Indeed, a recent report showed decreased
levels of HK2, PFKFB3, and GAPDH mRNA in skeletal muscle
from SBMA patients, accompanied by a glycolytic to oxidative
Figure 7. Regulators of Energy Metabolism
Are Sensitive to Peripheral polyQ AR
Expression
(A) Gene clusters identified through Ingenuity
Pathway Analysis. Canonical pathways are shown
in dark gray and upstream regulators in light gray.
(B) NR4A1 mRNA levels in quadriceps muscle of
WT, AR113Q, and AR113Q mice treated with AR-
targeted ASO or control ASO (SCRAMBLE) from 6
to 14 weeks of age (mean ± SEM; n = 3/group).
**p < 0.01 by one-way ANOVA.
(C) Expression of NR4A1 and target genes that
regulate carbohydrate metabolism in gastrocne-
mius muscles of control WT male mice following
sciatic nerve transection (mean ± SEM; n = 3/
group). *p < 0.05; **p < 0.01 by one-way ANOVA.shift in muscle fibers (Rocchi et al., 2016). These alterations may
have contributed to the modest effects of exercise observed in a
randomized study of SBMA patients (Shrader et al., 2015) and in
the poor tolerance of SBMA patients to aerobic exercise in an
observational study (Dahlqvist and Vissing, 2016). Moreover,
skeletal muscle plays a critical role in energy homeostasis for
the organism, accounting for 25% of energy expenditure in
the resting state. As such, altered energy utilization by skeletal
muscle may play a part in the systemic manifestations of dis-
ease. Recent studies have demonstrated elevated fasting
glucose as well as increased total cholesterol, low-density lipo-
protein cholesterol, and triglyceride levels in a cohort of SBMA
patients (Querin et al., 2016). These findings add to a growing
appreciation of non-neuronal phenotypes in this disorder and
raise the possibility that targeting metabolic alterations may alle-
viate disease manifestations. In support of this hypothesis is
recent work demonstrating that feeding mice a high-fat diet di-
minishes aspects of the SBMA phenotype (Rocchi et al., 2016).
Additional evidence suggests that enhancing anabolic support
of muscle is also beneficial in SBMA mice. Abrogation of
SUMO modification of the polyQ AR enhances its activity as a
ligand-dependent transcription factor, increases the expression
of genes related to mitochondria function in skeletal muscle, and
rescues both exercise endurance and type I muscle fiber atrophy
in mutant mice (Chua et al., 2015).
Derangements of energy utilization and homeostasis have
emerged as important components of the pathophysiology ofCell Repmany age-dependent neurodegenerative
disorders and of aging itself. The changes
documented here in AR113Q skeletal
muscle indicate that similar processes
occur in SBMA. Moreover, our analysis
suggests that these changes arise due
to expression of the polyQ AR in muscle
and demonstrates that they are mitigated
by peripherally targeted therapies. The
extent to which similar metabolic alter-
ations also impair function of lower motor
neurons in SBMA patients remains to be
more fully explored, although our initial
analysis of AR113Q mice suggests lesssevere gene expression changes in spinal cord than in skeletal
muscle. As such, we speculate that targeting the metabolic
phenotype trigged by expression of the polyQ AR may be
particularly effective in rescuing non-neuronal manifestations
of the disease, including important aspects of skeletal muscle
dysfunction.
EXPERIMENTAL PROCEDURES
Mice
Gene-targeted mice with an Ar allele containing 113 CAG repeats (AR113Q
mice) were previously described (Yu et al., 2006a, 2006b). Mice were group
housed in a specific-pathogen-free (SPF) facility, provided with chow and
water ad libitum, and maintained on a constant 12-hr light/12-hr dark cycle.
Genotypes were verified by PCR of DNA harvested from tail biopsy specimens
obtained shortly after weaning, using the forward primer 50-CCAGAA
TCTGTTCCAGAGCGTG-30 and the reverse primer 50-TGTTCCCCTGGACT
CAGATG-30.
ASO Treatment
AR113Q male mice and WT littermates were treated for 8 weeks with ASOs.
The 16-mer, 20,40-constrained ethyl gapmer ASO complementary to human
and mouse AR transcripts and the 20-mer control have been described previ-
ously (Lieberman et al., 2014). Subcutaneous administration of 50mg/kg body
weight of AR-targeted ASO (ASO1 from ref) or control ASO (SCRAMBLE;
control ASO from ref) was performed once a week from 6 to 14 weeks of
age (n = 3 per group). Quadriceps muscle was harvested at 14 weeks for anal-
ysis of mRNA expression.
Sciatic Nerve Transection
C57BL/6J male mice at 7 weeks of age were used for studies of denervated
muscle as detailed in the Supplemental Experimental Procedures.orts 17, 125–136, September 27, 2016 133
All procedures involving mice were approved by the University of Michigan
Committee on Use and Care of Animals, in accord with the NIH Guidelines for
the Care and Use of Experimental Animals.
Gene Expression
Total RNA was isolated from quadriceps and LA/BC muscles with TRIzol Re-
agent (Life Technologies) according to the manufacturer’s instructions. RNA
(1 mg) was reverse transcribed to cDNA using the High Capacity cDNA Reverse
TranscriptionKit (AppliedBiosystems).Gene-specificprimerswith FAM-labeled
probes were from Applied Biosystems: Nr4a1, Mm01300401_m1; Prkar2a,
Mm00435916_m1; Prkag3, Mm00463997_m1; Hk2, Mm00443385_m1;
Slc2a4, Mm01245502_m1; Phkg1, Mm02580948_m1; Pygm, Mm00478582_
m1; Ppargc1a, Mm01208835_m1; Ppargc1b, Mm00504720_m1; Bbc3,
Mm00519268_m1. AR-specific forward primer 50-CCAGTCCCAATTGTGT
CAAA-30 and reverse primer 50-TCCCTGGTACTGTCCAAACG-30 (Life Technol-
ogies) were used with Roche Universal Probe Library FAM-labeled probe #58
(catalog number 04688554001). Cpsf2-specific primers with VIC-labeled
probes (Applied Biosystems;Mm00489754_m1) were used as internal control.
qPCR was carried out using FastStart TaqMan Probe Master Mix (Roche) on
software supplied with a 7500 Real-Time PCR SDS System (Applied Bio-
systems). PCR cycling conditions were as follows: 50C for 2 min, 95C for
10 min, 40 cycles at 95C for 15 s, and 60C for 1 min.
RNA-Seq Data
For RNA-seq, cDNA was prepared into sequencer-ready fragment libraries
using the Illumina TruSeq mRNA-Seq Sample Prep Kit according to
manufacturer’s protocols, and sequenced on the Illumina HiSeq 2000 using
manufacturer’s protocols for paired-end, 100-nt sequencing. Samples were
multiplexed into pools of six samples each, and each pool was sequenced
on one lane of the sequencer. The software package Tuxedo Suite was
used for alignment, differential expression analysis, and postanalysis diagnos-
tics (Langmead et al., 2009; Trapnell et al., 2009, 2013). The reference tran-
scriptome (UCSC mm10) (http://genome.ucsc.edu/) was used for alignment.
Expression quantitation and differential expression analysis were performed
using CuffDiff (Cufflinks version 2.1.1). Genes and transcripts were identified
as differentially expressed based on three criteria: test status = OK, false dis-
covery rate (FDR) < 0.05, and fold changeR 1.5. Analysis of differentially ex-
pressed genes to identify significantly enriched functional categories was
performed using DAVID and IPA (QIAGEN). The heatmap was plotted in R
using the gplots and RcolorBrewer packages.
Transmission Electron Microscopy
Mice were perfused with 2.5% glutaraldehyde in 0.1 M phosphate buffer
(pH 7.4), and soleus muscle was collected. Ultra-thin tissue sections
were obtained with a diamond knife, placed on copper grids, and stained
with uranyl acetate and lead citrate. Image acquisition was performed with
a Philips CM-100 transmission electron microscope. Total mitochondria
number and vesicle-associated mitochondria were manually counted (n = 3
mice/group, R500 mitochondria/group). Mitochondria area (mm2) was
measured by ImageJ software (n = 3 mice/group, R250 mitochondria/
group).
mtDNA Copy Number
Genomic and mtDNA was isolated from LA/BC using the QIAamp DNA Micro
Kit (QIAGEN). D loop forward primer 50-GACCAACATAACTGTGGTGTCA-30
and reverse primer 50-ATTCTTCTCCGTAGGTGCGTCTAG-30 were designed
to quantify mtDNA; Beta-2 microglobulin (B2m) forward primer 50-TGTCAGA
TATGTCCTTCAGCAAGG-30 and reverse primer 50-TGCTTAACTCTGCAG
GCGTATG-30 were designed to quantify genomic DNA as an internal control.
qPCR was carried out using SYBR Select Master mix (Life Technologies) on
software supplied with a 7500 Real-Time PCR SDS System (Applied Bio-
systems). PCR cycling conditions were as follows: 50C for 2 min, 95C for
10 min, 40 cycles at 95C for 15 s, and 60C for 1 min. Data were expressed
as Ct values and used for the relative quantification of targets with the DDCt
calculation to give N-fold differences. Data were transformed through the
equation 2DDCt.134 Cell Reports 17, 125–136, September 27, 2016Mitochondria Uncoupling
Mitochondria were isolated from quadriceps muscles of WT and AR113Q
mice, and uncoupling was assessed as detailed in the Supplemental Experi-
mental Procedures.
CLAMS and Glucose Tolerance Test
Oxygen consumption (VO2), carbon dioxide production (VCO2), spontaneous
motor activity, and food intake were measured using CLAMS (Columbus In-
struments), an integrated open-circuit calorimeter equipped with an optical
beam activity monitor. This analysis and glucose tolerance testing was per-
formed by the University of Michigan Metabolomics Core and is described
in detail in the Supplemental Experimental Procedures.
Metabolomics
WT and AR113Q male mice ran on an Exer3/6 treadmill (Columbus Instru-
ments) with 25C slope for 15 min at increasing speeds (as described for
CLAMS analysis). Animals were induced into anesthesia at a dose of 5% iso-
flurane and then maintained by continuous inhalation of 2% isoflurane. Quad-
riceps muscles were collected and flash frozen in liquid nitrogen for LC-MS
and GC-MS analysis of metabolites by the University of Michigan Metabolo-
mics Core Facility, as detailed in the Supplemental Experimental Procedures.
Chronic Exercise
WT and AR113Q mice were run on an Exer3/6 treadmill (Columbus Instru-
ments) from 8 to 14 weeks of age for 30 min per day, 5 days per week, at
10-m/min fixed speed. Control mice were placed on an immobile treadmill
apparatus for the same amount of time. To analyze exercise capacity, a proto-
col for treadmill running was used as previously described (Chua et al., 2015).
In brief, mice underwent 2 days of training on a treadmill, with day 1 consisting
of 5 min of running at 8 m/min and day 2 consisting of 5 min of running at
8 m/min followed by 5min at 10m/min. On day 3, mice ran using a graded pro-
tocol consisting of 10 m/min for 40 min, then increasing speed by increments
of 1 m/min every 10 min for a total of 30 min. This was followed by increasing
speed at increments of 1 m/min every 5 min until mice were exhausted.
Exhaustion was defined as mice making no attempt to exercise for 5 s. Dis-
tance run and time to exhaustion were recorded. At the end of the 6-week
training period, body weight (g) and forelimb grip strength (g) were also
measured.
Immunoprecipitation and Western Blotting
Quadriceps muscles were homogenized in RIPA buffer containing one tablet
per 10 ml Complete Mini-Protease Inhibitor Mix (Roche), rotated for 2 hr at
4C, and centrifuged at 13,0003 g for 10 min at 4C. The supernatant fraction
(500 mg) was incubated on a rotator overnight at 4C with 10 mL AR antibody
(Millipore, PG-21) or nonimmune rabbit immunoglobulin G (IgG) (Santa Cruz
Biotechnology). Prewashed protein A-agarose beads (20 mL, Santa Cruz)
were added, and samples were incubated for one additional hour at 4C. Pro-
tein-antibody-bead complexes were washed six times in RIPA buffer in filtered
spin columns (Thermo Fisher Scientific), and proteins were eluted by boiling in
SDS-loading buffer for 5 min at 100C. Samples were then resolved on a 7.5%
SDS-PAGE gel.
Immunofluorescence Staining
Quadriceps and soleus/gastrocnemius muscles were placed on cork and
embedded in OCT (optimal cutting temperature) compound (Tissue-Tek)
immediately after collection. Cryosections were prepared using a Cryocut
1800 cryostat (Leica Biosystems) at 10 mm and placed on Superfrost Plus
Microscope Slides (Thermo Fischer Scientific). Briefly, slides were incubated
in acetone for 10 min, non-specific binding was blocked for 30 min at 37C
with 5% donkey serum in PBS-T (Tween 0.1% in PBS), and samples were
incubated overnight at 4C with the indicated antibodies in 1.5% donkey
serum in PBS-T. Fluorescent secondary antibody was then applied for 1 hr
at 37C in 1.5% donkey serum in PBS-T. Basement membrane was stained
with wheat germ agglutinin (WGA; green) at 5 mg/mL in PBS for 10 min at
room temperature (RT). The slides were mounted using Vectashield with
DAPI (Vector Laboratories) and sealed with nail polish. Muscle fiber size was
measured by ImageJ (n = 4 mice per group,R25 fibers per mouse).
Antibodies
The following antibodies were used: anti-AR (PG-21, Merck Millipore; N20,
Santa Cruz), anti-GAPDH (6C5, Novus Biologicals), type I/slow-twitch
heavy-chain myosin (A4.840, DSHB, University of Iowa), and type II/fast-twitch
heavy-chain myosin (Ab-2, Thermo Fisher Scientific). Horseradish peroxidase-
conjugated secondary antibodies used for western blot analysis were from
Bio-Rad. Goat anti-mouse IgG Alexa Fluor 555, goat anti-rabbit Alexa 488,
and wheat germ agglutinin Alexa 488 conjugate antibodies used for immuno-
fluorescence were from Life Technologies. Fluorescein isothiocyanate (FITC)-
conjugated donkey anti-mouse IgM was from Jackson ImmunoResearch
Laboratories.
Statistics
Data were analyzed using unpaired two-tailed Student’s t test or one-way
ANOVA with Newman-Keuls multiple comparison test in Prism 4 (GraphPad).
Statistical significancewas considered at p < 0.05. Low-rank thin-plate splines
were used to estimate the curves of energy expenditure and VO2 over time
(Ruppert and Wand, 2003). The model includes a random effect for the inter-
cept to account for correlations between measurements on the same subject.
At a time point, comparisons between groups (WT versus AR113Qmice) were
made using posterior distributions of the estimated outcome (such as VO2) for
each group. Statistical significance was determined by a 95% credible set for
the difference. If the credible set does not include zero, the difference is statis-
tically significant. WinBUGS (Version 1.4) was used for the analysis.
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